Vividion Therapeutics Commences P-I Study of VVD-130850 for Advanced Solid and Hematologic Tumors
Shots:
- Vividion Therapeutics has commenced the dosing of patients with VVD-130850 in the P-I trial for treating advanced solid and hematologic tumors
- The P-I study investigates the safety, tolerability, PK/PD and preliminary anti-tumor activity of VVD-130850 as monotx. and in combination with immune checkpoint inhibition for the treatment of advanced solid and hematologic tumors
- VVD-130850 (oral) is a small molecule that inhibits the binding of STAT3 to a novel allosteric site that directly inhibits DNA binding and STAT3 target genes’ expression in cancer cells
Ref: Tavros Therapeutics | Image: Tavros Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
